Type
|
Public |
---|---|
Traded as | NASDAQ: WBA NASDAQ-100 Component S&P 100 Component S&P 500 Component |
Industry | Pharmaceutical Retail |
Founded | Chicago, United States (December 31, 2014 (December 31, 2014)) |
Founders | Charles Rudolph Walgreen Walgreens (1901) John Boot Boots (1849) |
Headquarters | Deerfield, Illinois, United States |
Area served
|
Worldwide |
Key people
|
Jim Skinner (Executive Chairman) Stefano Pessina (Vice Chairman and CEO) |
Products | Drug store Pharmacy |
Revenue | US$117.35 billion (2016) |
Operating income
|
US$6.001 billion (2016) |
Net income
|
US$4.173 billion (2016) |
Total assets | US$72.68 billion (2016) |
Total equity | US$30.28 billion (2016) |
Number of employees
|
400,000 (2016) |
Divisions | Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale |
Subsidiaries | Alliance Healthcare Boots UK Boots Opticians Duane Reade drugstore.com Walgreens Farmacias Benavides Farmacias Ahumada |
Website | walgreensbootsalliance |
Walgreens Boots Alliance, Inc. is an American holding company headquartered in Deerfield, Illinois that owns Walgreens, Boots and a number of pharmaceutical manufacturing, wholesale and distribution companies. The company was formed on December 31, 2014 after Walgreens purchased the 55% stake in Switzerland-based Alliance Boots that it did not already own. Walgreens had previously purchased 45% of the company in 2012 with an option to purchase the remaining shares within three years.
Under the terms of the merger, the new company was organized into three divisions: Retail Pharmacy USA (Walgreens), Retail Pharmacy International (Boots), and Pharmaceutical Wholesale, incorporating Alliance Healthcare. The new holding company began trading on the NASDAQ on December 31, 2014.
The combined business has operations in over 25 countries. Walgreens had formerly operated solely within the United States and its territories, while Alliance Boots operated a more international business.
In October 2016, Walgreens Boots Alliance published its fourth quarter earnings report. Fiscal year 2016 totaled sales were $117.35 billion, up 13.4% from $103.44 in fiscal 2015, and GAAP net earnings decreased to $4.17 billion.
Walgreens and Duane Reade operate within the Retail Pharmacy USA division of Walgreens Boots Alliance. Both businesses sell prescription and non-prescription drugs, and a range of household items, including personal care and beauty products. Walgreens provides access to consumer goods and services, plus pharmacy, photo studio, health and wellness services in the United States through its retail drugstores. Walgreens had 8,230 drugstores as of December 2015. Walgreens runs several online stores, such as: Beauty.com, Drugstore.com and VisionDirect.com.
Walgreens has stores in all 50 US states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands.
On October 27, 2015, Walgreens announced the purchase of competitor Rite Aid for $17.2 billion.
On September 19, 2017, the Federal Trade Commission (FTC) approved a fourth deal agreement to purchase Rite Aid with 1,932 stores for $4.38 billion total.
Boots forms the main part of the Retail Pharmacy International division of the company. The Boots brand has a history stretching back over 160 years and is a familiar sight on Britain's high streets. Stores are located in prominent high street and city center locations as well as in local communities. Most branches include a pharmacy and focus on healthcare, personal care and cosmetic products, with most stores selling over the counter medicines. Larger stores typically offer a variety of healthcare services in addition to dispensing prescriptions, and chlamydia testing & treatment (private service). Optician services are also offered in many larger stores, with Boots Opticians providing eye tests along with the sale of spectacles and contact lenses.
Many stores also feature traditional photo processing and/or a HP picture kiosk where users of digital cameras and camera phones can create prints via Bluetooth, USB or CD. Larger stores usually offer a range of electrical equipment such as hairdryers, curlers and foot massagers, whilst selected stores offer a range of sandwiches, baguettes, wraps, salads and beverages.
Since 1936, there have been Boots stores outside the UK. Stores in countries as widely spread as New Zealand, Canada (see Pharma Plus) and France were all closed in the 1980s. Today, there are Boots branded stores outside the UK and Ireland in countries including United Arab Emirates, Bahrain, Norway, Lithuania, The Netherlands, and Thailand.
The remainder of the division is made up of the pharmacies Benavides in Mexico and Farmacias Ahumada (FASA) in Chile.
Alliance Healthcare forms the main part of Walgreens Boots Alliance's Pharmaceutical Wholesale division. It operates twice daily deliveries to more than 16,000 delivery points in the UK alone. Internationally, Alliance Healthcare supplies medicines, other healthcare products and related services to over 200,000 pharmacies, doctors, health centers and hospitals from over 350 distribution centers in 19 countries.
In addition to the wholesale of medicines and other healthcare products, Alliance Healthcare provides services to pharmaceutical manufacturers who are increasingly changing and adapting their approaches to distribution, while at the same time outsourcing non-core activities. These services include pre-wholesale and contract logistics, direct deliveries to pharmacies, and specialized medicine delivery including related home healthcare.
The division's Alphega Pharmacy network provides a range of services for independent pharmacies, including branding, professional training and patient care, retail support services and supply benefits together with pharmacy and IT support.
Boots produces a large number of brands that Alliance Boots and Walgreens sought to launch internationally following the first share purchase in 2012. The majority are produced by its subsidiary, BCM Limited, which manufactures both own-brand and third-party medicines, as well as cosmetic ranges including No 7, Kangol, FCUK, Soltan, and Botanics. BCM has facilities in the UK, Germany, and France. BCM Specials manufactures bespoke non-licensed medicines for UK hospital and retail pharmacies.
Launched in 1935, No7 is best known for its anti-aging beauty serums, developed in Nottingham that first appeared in 2007. The range comprises products designed to target the aging concerns of specific age groups. No7 became available in Walgreens and Duane Reade stores in the USA from November 2012, beginning in Los Angeles.
Launched in 1939, Soltan markets its UVA 5-star protection, a standard of protection developed by Boots and now adopted as the benchmark for suncare products in the UK. Although in both 2004 and 2015 Watchdog, a BBC consumer investigative TV program, and cited on BBC News; plus the consumer WHICH? Magazine, each did an investigation finding the 5-star rating was unsubstantiated, and skincare experts declared it to be far less safe than claimed.
First launched in 1995, the Botanics range, developed in partnership with the Royal Botanic Gardens, Kew, uses plant extracts in a variety of products, and includes a range of organic products. The Botanics range is also available through third party retailers.
The Boots own brand range of products includes skincare, medicines, healthcare products and many more. Boots Laboratories skincare range for independent pharmacy customers was launched in France and Portugal in 2008/09and is also sold in Spain, Italy and Germany.
Boots launched Almus, a brand of generic prescription drugs, in the UK in 2003. It is now sold in five countries and is an umbrella brand for a wide range of lower cost generic medicines. Alliance Boots placed considerable emphasis on the design of the packaging in an attempt to reduce the number of errors by the dispensing chemist and by the patient relating to incorrect dosage which can result in either a dangerous accidental overdose or an equally dangerous under dose.
Walgreens has a self-branded line of products, "Well at Walgreens".
In 2015, Walgreens Boots Alliance paid £140 million (about $250 million) for UK skincare brand Liz Earle Naturally Active, an Avon subsidiary since 2010. Liz Earle Beauty Co co-founder Liz Earle, 'one of the biggest names in the beauty industry' stayed on as an 'ambassador' after selling the company for an undisclosed sum and told her own Liz Earle Wellbeing magazine's website that '...alongside my new digital and print publishing venture...at the moment I’m still connected to Liz Earle Beauty Co and continue to work as a consultant to the brand that carries my name. I’m involved in new product development...'
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q2 2023 | 2023-06-29 | Future report Set alerts | |
Q1 2023 | 2023-01-05 | 1.16 | 1.16 |
Q4 2022 | 2022-10-13 | 0.80 | 0.80 |
Q3 2022 | 2022-06-30 | 0.96 | 0.96 |
Q2 2022 | 2022-03-31 | 1.59 | 1.59 |
Q1 2022 | 2022-01-06 | 1.68 | 1.68 |
Q4 2021 | 2021-10-14 | 1.17 | 1.17 |
Q3 2021 | 2021-07-01 | 1.38 | 1.38 |
Q2 2021 | 2021-03-31 | 1.26 | 1.26 |
Q1 2021 | 2021-01-07 | 1.22 | 1.22 |
2016-07-07 | Boost Price Target | Barclays PLC | Equal Weight | $76.00 to $79.00 |
2016-07-07 | Reiterated Rating | Jefferies Group | Hold to Neutral | |
2016-07-07 | Lower Price Target | FBR & Co | Market Perform | $90.00 to $85.00 |
2016-07-07 | Reiterated Rating | Evercore ISI | Buy | $93.00 |
2016-07-07 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
2016-06-27 | Reiterated Rating | Robert W. Baird | Outperform | $98.00 |
2016-06-13 | Reiterated Rating | Bank of America | Buy | |
2016-06-13 | Reiterated Rating | Bank of America Corp. | Buy | |
2016-06-10 | Reiterated Rating | Deutsche Bank | Buy | |
2016-06-10 | Reiterated Rating | Deutsche Bank AG | Buy | |
2016-06-07 | Reiterated Rating | Bank of America | Buy | $94.00 to $78.66 |
2016-04-19 | Reiterated Rating | Jefferies Group | Hold | |
2016-04-11 | Reiterated Rating | Leerink Swann | Buy | $95.00 |
2016-04-07 | Reiterated Rating | Credit Suisse | Buy | $95.00 |
2016-04-07 | Reiterated Rating | Credit Suisse Group AG | Buy | $95.00 |
2016-04-06 | Reiterated Rating | Evercore ISI | Buy | $95.00 |
2016-04-05 | Boost Price Target | Evercore ISI | Buy | $94.00 to $95.00 |
2016-04-02 | Reiterated Rating | Deutsche Bank | Buy | |
2016-04-01 | Reiterated Rating | Morgan Stanley | Buy | $95.00 |
2016-03-19 | Reiterated Rating | Deutsche Bank | Buy | $95.00 |
2016-03-16 | Initiated Coverage | Credit Suisse | Outperform Ratings | |
2016-03-15 | Reiterated Rating | Credit Suisse | Outperform | $100.00 to $92.00 |
2016-03-10 | Lower Price Target | Barclays | Equal Weight | $81.00 to $76.00 |
2016-03-10 | Lower Price Target | Barclays PLC | Equal Weight | $81.00 to $76.00 |
2016-03-01 | Upgrade | Mizuho | Neutral to Buy | $89.00 to $90.00 |
2016-02-12 | Reiterated Rating | FBR & Co. | Market Perform | |
2016-02-12 | Reiterated Rating | FBR & Co | Market Perform | |
2016-02-10 | Reiterated Rating | Deutsche Bank | Buy | |
2016-02-06 | Reiterated Rating | Citigroup Inc. | Buy | $111.00 to $88.00 |
2016-02-03 | Initiated Coverage | Atlantic Securities | Neutral | $88.00 |
2016-01-21 | Initiated Coverage | Robert W. Baird | Outperform | $96.00 |
2016-01-10 | Reiterated Rating | FBR & Co. | Market Perform | $90.00 |
2016-01-08 | Reiterated Rating | Guggenheim | Buy | |
2016-01-08 | Reiterated Rating | Leerink Swann | Buy | $105.00 |
2016-01-06 | Reiterated Rating | Deutsche Bank | Buy | $95.00 |
2016-01-06 | Upgrade | Evercore ISI | Hold to Buy | $94.50 |
2015-12-15 | Reiterated Rating | Jefferies Group | Hold | $95.00 to $90.00 |
2015-11-16 | Reiterated Rating | Leerink Swann | Buy | |
2015-11-16 | Upgrade | Raymond James | Market Perform to Outperform | |
2015-11-16 | Lower Price Target | Credit Suisse | Outperform | $110.00 to $100.00 |
2015-11-16 | Upgrade | Raymond James Financial Inc. | Market Perform to Outperform | |
2015-10-30 | Boost Price Target | Scotiabank | $100.00 to $101.00 | |
2015-10-29 | Reiterated Rating | S&P Equity Research | Buy | $99.00 |
2015-10-29 | Lower Price Target | Barclays | Equal Weight | $86.00 to $81.00 |
2015-10-28 | Reiterated Rating | Cowen and Company | Buy | $102.00 |
2015-10-28 | Upgrade | RBC Capital | Hold to Buy | $98.00 to $103.00 |
2015-10-28 | Boost Price Target | Jefferies Group | Hold | $90.00 to $105.00 |
2015-10-28 | Upgrade | Royal Bank Of Canada | Hold to Buy | $98.00 to $103.00 |
2015-10-21 | Lower Price Target | Cowen and Company | $104.00 to $102.00 | |
2015-09-09 | Upgrade | Cowen and Company | Market Perform to Outperform | $90.00 to $104.00 |
2015-07-16 | Upgrade | Credit Suisse | Neutral to Outperform | $90.00 to $110.00 |
2015-07-15 | Reiterated Rating | Citigroup Inc. | Buy | $107.00 to $111.00 |
2015-07-11 | Reiterated Rating | Macquarie | Buy | |
2015-07-10 | Reiterated Rating | FBR & Co. | Hold | |
2015-07-10 | Reiterated Rating | Macquarie | Outperform | $95.00 to $100.00 |
2015-07-10 | Reiterated Rating | Deutsche Bank | Buy | $89.00 to $95.00 |
2015-07-10 | Reiterated Rating | Barclays | Hold | $81.00 to $86.00 |
2015-07-10 | Upgrade | RBC Capital | Sector Perform to Outperform | |
2015-07-10 | Upgrade | Raymond James | Market Perform to Outperform | |
2015-07-10 | Boost Price Target | Leerink Swann | Outperform | $95.00 to $109.00 |
2015-07-10 | Reiterated Rating | Mizuho | Neutral | $86.00 to $89.00 |
2015-07-09 | Boost Price Target | Evercore ISI | Hold | $94.00 to $95.00 |
2015-07-09 | Reiterated Rating | William Blair | Outperform | |
2015-07-09 | Boost Price Target | FBR & Co. | Market Perform | $80.00 to $90.00 |
2015-06-30 | Boost Price Target | Leerink Swann | Outperform | $85.00 to $95.00 |
2015-06-09 | Initiated Coverage | Macquarie | Outperform | $95.00 |
2015-05-22 | Upgrade | Tigress Financial | Underperform to Neutral | |
2015-04-16 | Boost Price Target | Jefferies Group | Hold | $82.00 to $90.00 |
2015-04-13 | Boost Price Target | Citigroup Inc. | Buy | $88.00 to $107.00 |
2015-04-12 | Reiterated Rating | Deutsche Bank | Buy | $89.00 |
2015-04-08 | Boost Price Target | Mizuho | Neutral | $72.00 to $86.00 |
2015-04-02 | Set Price Target | Morgan Stanley | Buy | $91.00 |
2015-03-19 | Boost Price Target | Deutsche Bank | Buy | $82.00 to $89.00 |
2015-03-06 | Set Price Target | Credit Suisse | Hold | $85.00 |
2015-01-23 | Set Price Target | Deutsche Bank | Buy | $82.00 |
2015-01-13 | Downgrade | Jefferies Group | Buy to Hold | $67.00 to $82.00 |
2015-01-05 | Reiterated Rating | Deutsche Bank | Buy | $82.00 |
2014-12-26 | Boost Price Target | Credit Suisse | Neutral | $68.00 to $73.00 |
2014-12-24 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $70.00 to $88.00 |
2014-12-24 | Boost Price Target | Barclays | Equal Weight | $68.00 to $72.00 |
2014-12-24 | Boost Price Target | Leerink Swann | Outperform | $75.00 to $85.00 |
2014-12-24 | Boost Price Target | FBR & Co. | Hold | $70.00 |
2014-12-23 | Reiterated Rating | Bank of America | Hold | |
2014-12-23 | Set Price Target | Deutsche Bank | Buy | $82.00 |
2014-12-19 | Set Price Target | Cantor Fitzgerald | Hold | $56.00 |
2014-12-19 | Downgrade | SunTrust | Buy to Neutral | $72.00 to $77.00 |
2014-12-19 | Downgrade | SunTrust Banks Inc. | Buy to Neutral | $72.00 to $77.00 |
2014-12-10 | Initiated Coverage | Citigroup Inc. | Buy | $80.00 |
2014-12-09 | Downgrade | Mizuho | Buy to Neutral | $83.00 to $72.00 |
2014-12-05 | Boost Price Target | Evercore ISI | Hold | $63.00 to $71.50 |
2014-12-03 | Reiterated Rating | Bank of America | Neutral | |
2014-12-02 | Reiterated Rating | Morgan Stanley | Overweight | |
2014-11-05 | Reiterated Rating | Tigress Financial | Underperform | |
2014-10-06 | Lower Price Target | Deutsche Bank | Buy | $69.00 to $67.00 |
2014-10-01 | Reiterated Rating | Scotiabank | Outperform | |
2014-10-01 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $71.00 to $70.00 |
2014-10-01 | Reiterated Rating | Morgan Stanley | Overweight | $77.00 |
2014-09-30 | Lower Price Target | FBR & Co. | Market Perform | $66.00 to $62.00 |
2014-09-22 | Downgrade | Barclays | Overweight to Equal Weight | $92.00 to $68.00 |
2014-09-04 | Reiterated Rating | Evercore ISI | Neutral | |
2014-08-21 | Upgrade | Bank of America | Underperform to Neutral | $30.00 to $66.00 |
2014-08-12 | Lower Price Target | Deutsche Bank | $69.00 | |
2014-08-07 | Lower Price Target | BB&T Corp. | Buy | $80.00 to $65.00 |
2014-08-07 | Reiterated Rating | Cowen and Company | Market Perform | $74.00 to $62.00 |
2014-08-07 | Reiterated Rating | Jefferies Group | Buy | $87.00 to $69.00 |
2014-08-07 | Upgrade | Cantor Fitzgerald | Sell to Hold | $50.00 to $56.00 |
2014-08-06 | Lower Price Target | Evercore ISI | Cautious | $74.50 to $67.00 |
2014-06-26 | Reiterated Rating | Scotiabank | Sector Outperform | |
2014-06-25 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $74.00 to $77.00 |
2014-06-25 | Upgrade | Morgan Stanley | Hold to Overweight | $69.00 to $85.00 |
2014-06-25 | Lower Price Target | Goldman Sachs | $84.00 | |
2014-06-25 | Boost Price Target | FBR & Co. | Market Perform | $68.00 to $73.00 |
2014-06-25 | Upgrade | Jefferies Group | Hold to Buy | $69.00 to $87.00 |
2014-06-25 | Boost Price Target | BB&T Corp. | $72.00 to $80.00 | |
2014-06-23 | Boost Price Target | Susquehanna | Positive | $80.00 to $95.00 |
2014-06-20 | Boost Price Target | SunTrust | Buy | $82.00 to $87.00 |
2014-06-18 | Upgrade | Barclays | Equal Weight to Overweight | $56.00 to $92.00 |
2014-06-09 | Boost Price Target | Mizuho | Buy | $78.00 to $83.00 |
2014-06-02 | Reiterated Rating | Morgan Stanley | Overweight | $75.00 |
2014-05-14 | Downgrade | Cowen and Company | Outperform to Market Perform | |
2014-05-12 | Reiterated Rating | Morgan Stanley | Positive to Overweight | $75.00 |
2014-04-30 | Reiterated Rating | Jefferies Group | Hold | $62.00 to $69.00 |
2014-04-17 | Boost Price Target | Mizuho | Buy | $74.00 to $78.00 |
2014-04-15 | Reiterated Rating | Citigroup Inc. | Positive to Overweight | $75.00 |
2014-04-07 | Boost Price Target | Guggenheim | $52.00 to $75.00 | |
2014-03-27 | Boost Price Target | Morgan Stanley | $68.00 to $75.00 | |
2014-03-26 | Boost Price Target | Evercore ISI | Neutral | $69.00 to $70.00 |
2014-03-26 | Boost Price Target | BB&T Corp. | $72.00 | |
2014-03-26 | Boost Price Target | Cowen and Company | $69.00 to $74.00 | |
2014-03-26 | Downgrade | Macquarie | Outperform to Neutral | $64.00 to $68.00 |
2014-03-21 | Boost Price Target | SunTrust | $70.00 to $77.00 | |
2014-03-19 | Reiterated Rating | Morgan Stanley | Overweight | $68.00 |
2014-03-14 | Boost Price Target | Mizuho | Buy | $64.00 to $74.00 |
2014-03-12 | Boost Price Target | Goldman Sachs | Buy | $67.00 to $79.00 |
2014-03-04 | Boost Price Target | Susquehanna | $67.00 to $80.00 | |
2014-03-03 | Reiterated Rating | Morgan Stanley | Hold to Overweight | $68.00 |
2014-02-13 | Reiterated Rating | Morgan Stanley | Overweight | $68.00 |
2014-02-07 | Initiated Coverage | Leerink Swann | Outperform to Outperform | $68.00 |
2014-01-22 | Upgrade | Evercore ISI | Cautious to Neutral | $55.00 to $64.00 |
2013-12-30 | Downgrade | Ned Davis Research | Buy to Neutral | |
2013-12-18 | Reiterated Rating | Morgan Stanley | Overweight | $70.00 |
2013-12-17 | Lower Price Target | Goldman Sachs | Buy | $68.00 to $67.00 |
2013-12-04 | Boost Price Target | Mizuho | Buy | $62.00 to $65.00 |
2013-11-20 | Initiated Coverage | Deutsche Bank | Buy | $73.00 |
2013-11-19 | Downgrade | Raymond James | Outperform to Market Perform | $62.00 |
2013-11-04 | Boost Price Target | BB&T Corp. | Buy | $62.00 to $67.00 |
2013-10-31 | Boost Price Target | Evercore ISI | Neutral | $65.00 to $69.50 |
2013-10-24 | Initiated Coverage | FBR & Co. | Market Perform | $62.00 |
2013-10-07 | Initiated Coverage | Jefferies Group | Hold | $62.00 |
2013-10-07 | Upgrade | Wolfe Research | Underperform to Market Perform | |
2013-10-03 | Boost Price Target | Raymond James | Outperform | $55.00 to $62.00 |
2013-10-03 | Boost Price Target | Credit Suisse | Neutral | $45.00 to $55.00 |
2013-10-03 | Upgrade | Barrington Research | Market Perform to Outperform | $65.00 |
2013-10-02 | Boost Price Target | Cowen and Company | Outperform | $65.00 |
2013-10-02 | Boost Price Target | Citigroup Inc. | Buy | $63.00 to $64.00 |
2013-10-02 | Boost Price Target | BB&T Corp. | Buy | $59.00 to $62.00 |
2013-10-02 | Boost Price Target | Barclays | Equal Weight | $42.00 to $52.00 |
2013-10-01 | Boost Price Target | Goldman Sachs | Buy | $68.00 |
2013-09-30 | Set Price Target | Citigroup Inc. | $57.00 to $63.00 | |
2013-09-25 | Boost Price Target | Mizuho | Buy | $58.00 to $62.00 |
2013-09-23 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $70.00 |
2016-07-07 | Boost Price Target | Barclays PLC | Equal Weight | $76.00 to $79.00 |
2016-07-07 | Reiterated Rating | Jefferies Group | Hold to Neutral | |
2016-07-07 | Lower Price Target | FBR & Co | Market Perform | $90.00 to $85.00 |
2016-07-07 | Reiterated Rating | Evercore ISI | Buy | $93.00 |
2016-07-07 | Reiterated Rating | JPMorgan Chase & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In WBA 827 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 62.57M |
BlackRock Inc. | 58.81M |
STATE STREET CORP | 53.37M |
BlackRock Institutional Trust Company, N.A. | 22.90M |
Capital World Investors | 18.16M |
FMR LLC | 13.50M |
GEODE CAPITAL MANAGEMENT, LLC | 13.30M |
Invesco Ltd. | 12.03M |
BlackRock Fund Advisors | 11.10M |
MORGAN STANLEY | 10.82M |
BlackRock Group LTD | 9.10M |
WELLS FARGO & CO/MN | 8.81M |
NORTHERN TRUST CORP | 8.02M |
LEGAL & GENERAL GROUP PLC | 6.59M |
CITADEL ADVISORS LLC | 6.41M |